Current Headlines

  1. BMS And Celgene Collaborate For Combination Cancer Treatment Study

    Bristol-Myers Squibb Company (BMS) and Celgene Corporation announced Wednesday that they are collaborating on a Phase I clinical study, which will determine the efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo (nivolumab) and Celgene’s nab technology-based chemotherapy Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). The collaborating parties will study multiple types of tumors, including HER-2 negative metastatic breast cancer, pancreatic cancer, and nonsmall cell lung cancer (NSCLC).

  2. Pfizer Files NDA For Palbociclib In Breast Cancer With FDA

    Pfizer announced that it has completed the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its investigational drug palbociclib for the treatment of postmenopausal, treatment-naive women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

  3. Lilly, Boehringer Ingelheim Get Tentative FDA OK For Basaglar

    Eli Lilly together with its partner Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to Basaglar (insulin glargine injection) indicated for the improvement of glycemic control in adult patients with Type 2 diabetes.

  4. Novartis Signs Investment And Option Agreement With Gamida Cell

    Gamida Cell, a company focused on stem cell expansion technologies and therapeutics, announced that it has entered into an investment and option agreement with pharmaceutical giant Novartis.

  5. Southwest Airlines Cargo Earns Highest Honors For Performance

    Southwest Airlines Cargo is celebrating winning the Quest for Quality Award, awarded by Logistics Management Magazine, for 18 consecutive years. 

  6. Stem Cell Research ‘Holy Grail’ Uncovered, Thanks to Zebrafish

    With help from the zebrafish, a team of Australian researchers has uncovered how hematopoietic stem cells (HSC) renew themselves, considered by many to be the ‘holy grail’ of stem cell research.

  7. Jell-O-Like Biomaterial Could Hold Key To Cancer Cell Destruction

    Scientists from Penn State University reported that a biomaterial made of tiny molecules was able to attract and destroy cancer cells.

  8. MicroVAX Begins Phase I Clinical Trial For New Cancer Vaccine

    MicroVAX, a biotech company in Virginia, will begin a phase I clinical trial for its unique and proprietary vaccine platform for patients with breast, prostate, colon, ovary and lung cancers that have relapsed after initial therapy. The trial is sponsored by the Singapore Clinical Research Institute (SCRI) and will be conducted by Dr. Toh Han Chong, Senior Consultant and Deputy Director at the National Cancer Center Singapore (NCCS).

  9. Scientists Use Soil Bacteria To Kill, Shrink Tumors

    Scientists from the Johns Hopkins Kimmel Cancer Center reported that a modified version of common soil bacteria injected into solid cancers attacked and shrank many of the tumors.

  10. New Treatments For Multiple Sclerosis Show Promising Results
    Researchers at the Victoria University of Wellington are developing several new and promising treatments for multiple sclerosis (MS), including some common anti-psychotic agents.